Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: FSD2

Gene summary for FSD2

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

FSD2

Gene ID

123722

Gene namefibronectin type III and SPRY domain containing 2
Gene AliasSPRYD1
Cytomap15q25.2
Gene Typeprotein-coding
GO ID

GO:0005575

UniProtAcc

A1L4K1


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
123722FSD2HCC1HumanLiverHCC6.31e-221.60e+000.5336
123722FSD2HCC2HumanLiverHCC6.04e-302.02e+000.5341
123722FSD2HCC5HumanLiverHCC4.49e-231.51e+000.4932
Page: 1 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:00450567Oral cavityOSCCtranscytosis16/730521/187235.99e-043.39e-0316
GO:00344406Oral cavityOSCClipid oxidation59/7305108/187237.01e-043.89e-0359
GO:004592710Oral cavityOSCCpositive regulation of growth125/7305259/187231.44e-036.97e-03125
GO:00066357Oral cavityOSCCfatty acid beta-oxidation42/730574/187231.47e-037.09e-0342
GO:00442826Oral cavityOSCCsmall molecule catabolic process174/7305376/187232.25e-031.00e-02174
GO:00442426Oral cavityOSCCcellular lipid catabolic process104/7305214/187232.61e-031.15e-02104
GO:19012642Oral cavityOSCCcarbohydrate derivative transport44/730580/187232.67e-031.16e-0244
GO:00468906Oral cavityOSCCregulation of lipid biosynthetic process85/7305171/187232.79e-031.21e-0285
GO:00192167Oral cavityOSCCregulation of lipid metabolic process154/7305331/187233.00e-031.30e-02154
GO:00620128Oral cavityOSCCregulation of small molecule metabolic process155/7305334/187233.30e-031.41e-02155
GO:00464743Oral cavityOSCCglycerophospholipid biosynthetic process102/7305211/187233.50e-031.48e-02102
GO:00066445Oral cavityOSCCphospholipid metabolic process175/7305383/187234.21e-031.71e-02175
GO:00065756Oral cavityOSCCcellular modified amino acid metabolic process91/7305188/187235.33e-032.07e-0291
GO:001635810Oral cavityOSCCdendrite development113/7305243/187231.00e-023.49e-02113
GO:01501723Oral cavityOSCCregulation of phosphatidylcholine metabolic process8/730510/187231.03e-023.53e-028
GO:00352646Oral cavityOSCCmulticellular organism growth65/7305132/187231.06e-023.60e-0265
GO:00215435Oral cavityOSCCpallium development81/7305169/187231.11e-023.76e-0281
GO:0009895110Oral cavityLPnegative regulation of catabolic process128/4623320/187238.36e-103.91e-08128
GO:0031330110Oral cavityLPnegative regulation of cellular catabolic process107/4623262/187235.25e-092.16e-07107
GO:0071496110Oral cavityLPcellular response to external stimulus124/4623320/187231.44e-085.36e-07124
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
FSD2SNVMissense_Mutationrs200109394c.1411N>Tp.Pro471Serp.P471SA1L4K1protein_codingdeleterious(0.04)probably_damaging(1)TCGA-A7-A26E-01Breastbreast invasive carcinomaFemale>=65III/IVChemotherapycytoxanSD
FSD2SNVMissense_Mutationc.413N>Tp.Gly138Valp.G138VA1L4K1protein_codingdeleterious(0.04)benign(0.348)TCGA-AN-A0AM-01Breastbreast invasive carcinomaFemale<65I/IIUnknownUnknownSD
FSD2SNVMissense_Mutationrs774888742c.1499N>Tp.Ser500Leup.S500LA1L4K1protein_codingdeleterious(0)probably_damaging(0.998)TCGA-D8-A142-01Breastbreast invasive carcinomaFemale>=65I/IIChemotherapycyclophosphamidSD
FSD2SNVMissense_Mutationc.923C>Ap.Thr308Lysp.T308KA1L4K1protein_codingdeleterious(0.01)benign(0.435)TCGA-D8-A1X9-01Breastbreast invasive carcinomaFemale>=65I/IIChemotherapyadriamycin+cyclophosphamideSD
FSD2SNVMissense_Mutationrs781225191c.388G>Ap.Glu130Lysp.E130KA1L4K1protein_codingtolerated(0.07)benign(0.096)TCGA-DS-A0VK-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycarboplatinPD
FSD2SNVMissense_Mutationnovelc.493N>Tp.Val165Phep.V165FA1L4K1protein_codingdeleterious(0)probably_damaging(0.957)TCGA-DS-A1OC-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapygemcitabineSD
FSD2SNVMissense_Mutationc.520N>Ap.Glu174Lysp.E174KA1L4K1protein_codingtolerated(0.07)possibly_damaging(0.867)TCGA-JW-A5VL-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
FSD2SNVMissense_Mutationc.1398G>Ap.Met466Ilep.M466IA1L4K1protein_codingtolerated(0.05)benign(0.003)TCGA-LP-A4AV-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
FSD2SNVMissense_Mutationc.88G>Ap.Glu30Lysp.E30KA1L4K1protein_codingtolerated(0.41)benign(0.006)TCGA-VS-A8QC-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapypaclitaxelPD
FSD2SNVMissense_Mutationnovelc.586N>Ap.Glu196Lysp.E196KA1L4K1protein_codingdeleterious(0.04)benign(0.157)TCGA-ZJ-AAXU-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
Page: 1 2 3 4 5 6 7 8 9 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1